Autolus Therapeutics plc (NASDAQ:AUTL) is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, AUTL is expected to report 3Q20 loss of $ 0.71 per share from revenue of $ 0.30 million.
For the full year, analysts anticipate top line of $ 1.14 million, while looking forward to loss of $ 2.7 per share bottom line.
Previous Quarter Performance
Autolus Therapeutics plc reported loss for the second quarter of $ 0.62 per share, from the revenue of $ 0.29 million. The quarterly revenues dropped 14.71 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.71 per share from $ 0.38 million in revenue. The bottom line results beat street analysts by $ 0.09 or 12.68 percent, at the same time, top line results fell short of analysts by $ 0.09 million or 23.68 percent.
Stock Performance
Shares of Autolus Therapeutics plc traded up $ 0.58 or 5.11 percent on Wednesday, reaching $ 11.94 with volume of 54.40 thousand shares. Autolus Therapeutics plc has traded high as $ 12.17 and has cracked $ 11.41 on the downward trend
The closing price of $ 11.94, representing a 278.67 % increase from the 52 week low of $ 3.00 and a 33.92 % decrease over the 52 week high of $ 17.19.
The company has a market capital of $ 623.87 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Autolus Therapeutics plc will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.autolus.com
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
